← All trials
NCT05722405
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jul 31, 2025
- First posted
- Feb 10, 2023
- Last posted
- Feb 10, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Nanchang UniversityCollaborator
- Dongyang People's HospitalCollaborator
- Huizhou People's Central HospitalCollaborator
- Lishui Country People's HospitalCollaborator
- Shaoxing People's HospitalCollaborator
- Shaoxing Second HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.